Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer

ACoP15 (Nov 2024), Poster: M-074
Mc Laughlin AM, Pan Y, Friberg Hietala S, Peigné S, Uema D, Zwirtes R, Dai D, Zhou D, Tajima N, Garimella T, Abutarif M, Hong Y.
ConferenceOncologyPharmacometricsTrial design and analysis

Pharmetheus Affiliates

Portrait-of-Anna-Mc-Laughlin_Pharmetheus
Senior Director, MIDD Consultant

Anna Mc Laughlin

See bio
Portrait-of-Sophie-Peigne-Pharmetheus
Senior Director, MIDD Consultant

Sophie Peigné

See bio
Portrait-of-Sofia-Friberg-Hietala_Pharmetheus
Principal Director, Client Operations Manager

Sofia Friberg Hietala

See bio